investigacion

Study distinguishes breast cancer risks among BRCA2 variants

Redacción El Periódico de la Salud · 19 de noviembre de 2026 a las 0:27 · Fuente: doi.org

Mayo Clinic-led research examines genetic changes that retain some function. The findings may refine genetic counselling, but do not support changing an individual screening plan without specialist advice.

A study led by Mayo Clinic researchers and published in Nature Communications on November 17, 2026 examines why certain BRCA2 variants do not carry the same breast cancer risk. The team investigated 70 candidate variants that retain part of the protein's function in DNA repair.

Among these, 34 variants with stronger functional effects were associated with moderate breast cancer risk and later diagnosis compared with higher-penetrance pathogenic variants. Combining functional evidence with variant-classification criteria allowed 14 variants to be classified as likely pathogenic. These counts describe genetic variants, not percentages of patients.

The research combines functional experiments and genetic data analysis; it is not a trial demonstrating a new treatment. Its potential lies in making variant-specific risk assessment more precise. BRCA2 results need interpretation by genetics professionals alongside personal and family history. The findings do not mean there is no risk, and they do not justify stopping screening or making surgical decisions without an individual assessment.

Redacción El Periódico de la Salud

← Más noticias